We are live on ! Find out more
TLP

Tri Locum Partners Portfolio holdings

AUM $713M
1-Year Est. Return 68.92%
This Fund
S&P 500
This Quarter Est. Return
+31.93%
1 Year Est. Return
+68.92%
3 Year Est. Return
+377.81%
5 Year Est. Return
+1,289.15%
10 Year Est. Return
–
AUM
$254M
AUM Growth
+$2.37M
Cap. Flow
-$21.5M
Cap. Flow %
-8.46%
Top 10 Hldgs %
62.37%
Holding
58
New
30
Increased
6
Reduced
5
Closed
17

Top Buys

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$21.3M
2
LLY icon
Eli Lilly
LLY
+$19.9M
3
CCXI
ChemoCentryx, Inc.
CCXI
+$14.8M
4
ARGX icon
argenx
ARGX
+$14.7M
5
APLS
Apellis Pharmaceuticals
APLS
+$12.5M

Top Sells

Rank Stock Value
1
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$28.6M
2
BAX icon
Baxter International
BAX
+$25.1M
3
WBA
Walgreens Boots Alliance
WBA
+$14.7M
4
MRK icon
Merck
MRK
+$13.7M
5
MDT icon
Medtronic
MDT
+$13M

Sector Composition

Rank Sector Weight
1 Healthcare 87.13%
2 Consumer Staples 4.82%
3 Financials 0%
4 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RAPT
26
DELISTED
RAPT Therapeutics
RAPT
$1.77M 0.7%
+6,018
New +$1.61M
TCDA
27
DELISTED
Tricida, Inc. Common Stock
TCDA
$1.62M 0.64%
+169,786
New +$1.1M
CYTK icon
28
Cytokinetics
CYTK
$10.5B
$1.52M 0.6%
+33,379
New +$1.29M
NVAX icon
29
CALL
Novavax
NVAX
$1.24B
$1.52M 0.6%
10,600
-8,700
-45% -$1.49M
ONEM
30
DELISTED
1Life Healthcare
ONEM
$1.49M 0.59%
+84,748
New +$1.64M
ITCI
31
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$1.37M 0.54%
+26,177
New +$1.1M
AMWL icon
32
American Well
AMWL
$172M
$1.36M 0.53%
+11,244
New +$1.71M
CANO
33
DELISTED
Cano Health, Inc.
CANO
$1.26M 0.5%
+1,415
New +$1.49M
VIR icon
34
PUT
Vir Biotechnology
VIR
$1.53B
$1.26M 0.49%
+30,000
New +$1.18M
SRRK icon
35
Scholar Rock
SRRK
$5.6B
$1.01M 0.4%
+40,571
New +$1.12M
ACRS icon
36
Aclaris Therapeutics
ACRS
$789M
$806K 0.32%
+55,433
New +$840K
XENE icon
37
Xenon Pharmaceuticals
XENE
$6.11B
$782K 0.31%
25,043
-239,091
-91% -$7.14M
FEMY icon
38
Femasys
FEMY
$9.18M
$568K 0.22%
7,282
-2,248
-24% -$262K
DRRX
39
DELISTED
DURECT Corp
DRRX
$26K 0.01%
+2,639
New +$29.2K
AWH
40
DELISTED
Aspira Women's Health Inc. Common Stock
AWH
$19K 0.01%
+725
New +$27.5K
ATHX
41
DELISTED
Athersys, Inc. Common Stock
ATHX
$18K 0.01%
+778
New +$22.3K
AVDL
42
DELISTED
Avadel Pharmaceuticals
AVDL
– –
-148,355
Closed -$1.45M
BAX icon
43
Baxter International
BAX
$14.4B
– –
-312,400
Closed -$25.1M
BNTX icon
44
BioNTech
BNTX
$23.4B
– –
-5,506
Closed -$1.5M
BGMS
45
Bio Green Med Solution Inc
BGMS
$5.57M
– –
-145
Closed -$2.76M
CYPH
46
Cypherpunk Technologies Inc
CYPH
$71.3M
– –
-181,067
Closed -$7.26M
MDT icon
47
Medtronic
MDT
$110B
– –
-104,070
Closed -$13M
MRK icon
48
CALL
Merck
MRK
$316B
– –
-150,500
Closed -$11.3M
MRK icon
49
Merck
MRK
$316B
– –
-181,765
Closed -$13.7M
REGN icon
50
Regeneron Pharmaceuticals
REGN
$77.7B
– –
-13,950
Closed -$8.44M
1
2
3

Similar funds

DCM
Defilade Capital Management Emeryville, California $712M AUM
AMPWP
Alvarez & Marsal Private Wealth Partners West Palm Beach, Florida $712M AUM
DCM
Dimension Capital Management Coral Gables, Florida $713M AUM 18.57% 1-Year Est. Return
IWP
Insight Wealth Partners Plano, Texas $713M AUM 16.55% 1-Year Est. Return
PCS
Personal CFO Solutions Chester, New Jersey $712M AUM 25.3% 1-Year Est. Return
ACGDR
Atmos Capital Gestao de Recursos Leblon - Rio De Janeiro, Brazil $714M AUM 35.97% 1-Year Est. Return
GEA
Glen Eagle Advisors Kingston, New Jersey $714M AUM 18.87% 1-Year Est. Return
ECM
EagleClaw Capital Management Boston, Massachusetts $714M AUM 24.24% 1-Year Est. Return

Tri Locum Partners's Q4 2021 Portfolio in Review

As of Q4 2021, Tri Locum Partners held 58 positions worth $254M, up 0.94% from $252M the previous quarter. Its ten largest holdings account for 62% of the portfolio.

Tri Locum Partners withdrew a net $21.5M in Q4 2021, closing 17 positions and reducing 5 holdings. Its most notable exit was Horizon Therapeutics Public Limited Company Ordinary Shares, an estimated $28.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 87% of assets, up from 76% a quarter earlier, followed by Consumer Staples and Financials.

Against the trend, Tri Locum Partners opened a new position in AbbVie worth $24.4M.

  • Tri Locum Partners's largest Q4 2021 buy was AbbVie: 179,950 shares worth $24.4M.
  • Tri Locum Partners added most to ChemoCentryx, Inc. in Q4 2021, an estimated $14.8M increase.
  • Tri Locum Partners's biggest Q4 2021 reduction was Xenon Pharmaceuticals, cutting an estimated $7.14M.
  • Tri Locum Partners fully exited Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2021, selling an estimated $28.6M.
  • Tri Locum Partners's ten largest holdings make up 62% of its $254M portfolio in Q4 2021.
  • Tri Locum Partners opened 30 new positions and closed 17 in Q4 2021.
  • Tri Locum Partners's portfolio value rose 0.94% quarter-over-quarter to $254M.

Based on Tri Locum Partners's 13F filing for Q4 2021, filed 14 Feb 2022.